دورية أكاديمية
أعرض في EDS

Comprehensive Acute Kidney Injury Survivor Care: Protocol for the Randomized Acute Kidney Injury in Care Transitions Pilot Trial.

التفاصيل البيبلوغرافية
العنوان: Comprehensive Acute Kidney Injury Survivor Care: Protocol for the Randomized Acute Kidney Injury in Care Transitions Pilot Trial.
المؤلفون: May HP; Mayo Clinic, Rochester, MN, United States., Griffin JM; Mayo Clinic, Rochester, MN, United States., Herges JR; Mayo Clinic, Rochester, MN, United States., Kashani KB; Mayo Clinic, Rochester, MN, United States., Kattah AG; Mayo Clinic, Rochester, MN, United States., Mara KC; Mayo Clinic, Rochester, MN, United States., McCoy RG; Mayo Clinic, Rochester, MN, United States., Rule AD; Mayo Clinic, Rochester, MN, United States., Tinaglia AG; Mayo Clinic, Rochester, MN, United States., Barreto EF; Mayo Clinic, Rochester, MN, United States.
المصدر: JMIR research protocols [JMIR Res Protoc] 2023 May 22; Vol. 12, pp. e48109. Date of Electronic Publication: 2023 May 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101599504 Publication Model: Electronic Cited Medium: Print ISSN: 1929-0748 (Print) Linking ISSN: 19290748 NLM ISO Abbreviation: JMIR Res Protoc Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Toronto : JMIR Publications
مستخلص: Background: Innovative care models are needed to address gaps in kidney care follow-up among acute kidney injury (AKI) survivors. We developed the multidisciplinary AKI in Care Transitions (ACT) program, which embeds post-AKI care in patients' primary care clinic.
Objective: The objective of this randomized pilot trial is to test the feasibility and acceptability of the ACT program and study protocol, including recruitment and retention, procedures, and outcome measures.
Methods: The study will be conducted at Mayo Clinic in Rochester, Minnesota, a tertiary care center with a local primary care practice. Individuals who are included have stage 3 AKI during their hospitalization, do not require dialysis at discharge, have a local primary care provider, and are discharged to their home. Patients unable or unwilling to provide informed consent and recipients of any transplant within 100 days of enrollment are excluded. Consented patients are randomized to receive the intervention (ie, ACT program) or usual care. The ACT program intervention includes predischarge kidney health education from nurses and coordinated postdischarge laboratory monitoring (serum creatinine and urine protein assessment) and follow-up with a primary care provider and pharmacist within 14 days. The usual care group receives no specific study-related intervention, and any aspects of AKI care are at the direction of the treating team. This study will examine the feasibility of the ACT program, including recruitment, randomization and retention in a trial setting, and intervention fidelity. The feasibility and acceptability of participating in the ACT program will also be examined in qualitative interviews with patients and staff and through surveys. Qualitative interviews will be deductively and inductively coded and themes compared across data types. Observations of clinical encounters will be examined for discussion and care plans related to kidney health. Descriptive analyses will summarize quantitative measures of the feasibility and acceptability of ACT. Participants' knowledge about kidney health, quality of life, and process outcomes (eg, type and timing of laboratory assessments) will be described for both groups. Clinical outcomes (eg, unplanned rehospitalization) up to 12 months will be compared with Cox proportional hazards models.
Results: This study received funding from the Agency for Health Care Research and Quality on April 21, 2021, and was approved by the Institutional Review Board on December 14, 2021. As of March 14, 2023, seventeen participants each have been enrolled in the intervention and usual care groups.
Conclusions: Feasible and generalizable AKI survivor care delivery models are needed to improve care processes and health outcomes. This pilot trial will test the ACT program, which uses a multidisciplinary model focused on primary care to address this gap.
Trial Registration: ClinicalTrials.gov NCT05184894; https://www.clinicaltrials.gov/ct2/show/NCT05184894.
International Registered Report Identifier (irrid): DERR1-10.2196/48109.
(©Heather P May, Joan M Griffin, Joseph R Herges, Kianoush B Kashani, Andrea G Kattah, Kristin C Mara, Rozalina G McCoy, Andrew D Rule, Angeliki G Tinaglia, Erin F Barreto. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 22.05.2023.)
References: Kidney Med. 2022 Dec 15;5(4):100586. (PMID: 36970221)
Implement Sci. 2017 Aug 29;12(1):108. (PMID: 28851459)
Am J Nephrol. 2018;47(3):200-207. (PMID: 29558745)
Lancet. 2022 Apr 16;399(10334):1551-1560. (PMID: 35430022)
Can J Kidney Health Dis. 2019 Feb 21;6:2054358119830700. (PMID: 30815269)
Crit Care. 2021 Aug 31;25(1):322. (PMID: 34465357)
BMC Med Inform Decis Mak. 2016 Jul 20;16:96. (PMID: 27439359)
Kidney Int Rep. 2020 Aug 06;5(10):1634-1642. (PMID: 33102955)
J Crit Care. 2015 Oct;30(5):988-93. (PMID: 26070247)
Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 01;2(1):4-9. (PMID: 30225426)
Am J Nephrol. 2021;52(10-11):817-826. (PMID: 34727542)
J Crit Care. 2018 Aug;46:141-148. (PMID: 29929705)
Adv Chronic Kidney Dis. 2013 Jul;20(4):326-35. (PMID: 23809285)
Am J Kidney Dis. 2017 Mar;69(3 Suppl 1):A7-A8. (PMID: 28236831)
Implement Sci. 2009 Aug 07;4:50. (PMID: 19664226)
Clin J Am Soc Nephrol. 2021 Jul;16(7):1005-1014. (PMID: 34021031)
Nephron Clin Pract. 2012;120(4):c179-84. (PMID: 22890468)
BMC Health Serv Res. 2016 Aug 30;16:449. (PMID: 27577888)
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):941-953. (PMID: 31101671)
Hosp Pharm. 2013 May;48(5):380-8. (PMID: 24421494)
Kidney360. 2021 Jul 13;2(9):1424-1433. (PMID: 35373103)
Can J Kidney Health Dis. 2022 Mar 6;9:20543581221081258. (PMID: 35284082)
Am J Nephrol. 2022;53(4):273-281. (PMID: 35294951)
Am J Nephrol. 2019;49(6):449-459. (PMID: 30995659)
J Health Commun. 2012;17 Suppl 3:141-59. (PMID: 23030567)
Ann Pharmacother. 2018 Aug;52(8):713-723. (PMID: 29457491)
PLoS One. 2019 Aug 22;14(8):e0221325. (PMID: 31437198)
Adv Chronic Kidney Dis. 2017 Jul;24(4):246-252. (PMID: 28778365)
معلومات مُعتمدة: R03 HS028060 United States HS AHRQ HHS
فهرسة مساهمة: Keywords: acute kidney injury; acute renal failure; care transitions; chronic kidney disease; nephrologists; randomized controlled trials
سلسلة جزيئية: ClinicalTrials.gov NCT05184894
تواريخ الأحداث: Date Created: 20230522 Latest Revision: 20230920
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10242466
DOI: 10.2196/48109
PMID: 37213187
قاعدة البيانات: MEDLINE
الوصف
تدمد:1929-0748
DOI:10.2196/48109